WO2007013894A3 - Phospholipid ether analogs for detecting and treating cancer - Google Patents

Phospholipid ether analogs for detecting and treating cancer Download PDF

Info

Publication number
WO2007013894A3
WO2007013894A3 PCT/US2005/047657 US2005047657W WO2007013894A3 WO 2007013894 A3 WO2007013894 A3 WO 2007013894A3 US 2005047657 W US2005047657 W US 2005047657W WO 2007013894 A3 WO2007013894 A3 WO 2007013894A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
detecting
phospholipid ether
ether analogs
treating cancer
Prior art date
Application number
PCT/US2005/047657
Other languages
French (fr)
Other versions
WO2007013894A2 (en
WO2007013894A9 (en
Inventor
Jamey Weichert
Marc Longino
Anatoly Pinchuk
Original Assignee
Cellectar Llc
Jamey Weichert
Marc Longino
Anatoly Pinchuk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Llc, Jamey Weichert, Marc Longino, Anatoly Pinchuk filed Critical Cellectar Llc
Priority to CA002591907A priority Critical patent/CA2591907A1/en
Priority to MX2007007497A priority patent/MX2007007497A/en
Priority to EP05858499A priority patent/EP1833514A2/en
Priority to JP2007548624A priority patent/JP2008545614A/en
Priority to US11/382,645 priority patent/US7632644B2/en
Publication of WO2007013894A2 publication Critical patent/WO2007013894A2/en
Publication of WO2007013894A9 publication Critical patent/WO2007013894A9/en
Publication of WO2007013894A3 publication Critical patent/WO2007013894A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma,Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs
PCT/US2005/047657 2004-03-02 2005-12-20 Phospholipid ether analogs for detecting and treating cancer WO2007013894A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002591907A CA2591907A1 (en) 2004-12-20 2005-12-20 Phospholipid ether analogs for detecting and treating cancer
MX2007007497A MX2007007497A (en) 2004-12-20 2005-12-20 Phospholipid ether analogs for detecting and treating cancer.
EP05858499A EP1833514A2 (en) 2004-12-20 2005-12-20 Phospholipid ether analogs for detecting and treating cancer
JP2007548624A JP2008545614A (en) 2004-12-20 2005-12-20 Phospholipid ether analogs for cancer detection and therapy
US11/382,645 US7632644B2 (en) 2004-03-02 2006-05-10 Imaging and selective retention of phospholipid ether analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59319004P 2004-12-20 2004-12-20
US60/593,190 2004-12-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/006681 Continuation-In-Part WO2005084716A2 (en) 2004-03-02 2005-03-02 Phospholipid analogs for diagnosis and treatment of cancer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/024259 Continuation-In-Part WO2006014589A2 (en) 2004-03-02 2005-07-08 Virtual colonoscopy with radiolabeled phospholipid ether analogs
US11/382,645 Continuation-In-Part US7632644B2 (en) 2004-03-02 2006-05-10 Imaging and selective retention of phospholipid ether analogs

Publications (3)

Publication Number Publication Date
WO2007013894A2 WO2007013894A2 (en) 2007-02-01
WO2007013894A9 WO2007013894A9 (en) 2007-03-29
WO2007013894A3 true WO2007013894A3 (en) 2007-04-19

Family

ID=37564093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/047657 WO2007013894A2 (en) 2004-03-02 2005-12-20 Phospholipid ether analogs for detecting and treating cancer

Country Status (6)

Country Link
EP (1) EP1833514A2 (en)
JP (1) JP2008545614A (en)
KR (1) KR20080005178A (en)
CA (1) CA2591907A1 (en)
MX (1) MX2007007497A (en)
WO (1) WO2007013894A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
DE602005015687D1 (en) 2004-03-02 2009-09-10 Cellectar Inc PHOSPHOLIPIDE ANALOGUE FOR THE TREATMENT OF CANCER
US7700075B2 (en) * 2004-07-08 2010-04-20 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs
JP5702366B2 (en) * 2009-05-11 2015-04-15 セレクター，インコーポレイティド Fluorescent phospholipid ether compounds, compositions and uses thereof
EP4248999A3 (en) 2009-06-12 2023-11-15 Cellectar, Inc. Ether phospholipid compounds for treating cancer and imaging and detection of cancer stem cells
EP2475400A2 (en) * 2009-09-11 2012-07-18 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
EP3750545B1 (en) * 2014-11-17 2024-03-27 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
JP6666757B2 (en) * 2016-03-10 2020-03-18 日本メジフィジックス株式会社 Method for quantifying polyoxyethylene nonionic surfactant and method for producing radiopharmaceutical preparation
CA3027497C (en) 2016-06-14 2023-12-05 Cellectar Biosciences, Inc. Phospholipid ether analogs for the identification and isolation of circulating tumor cells
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
JP7490361B2 (en) * 2016-07-18 2024-05-27 ウイスコンシン アラムナイ リサーチ ファウンデーシヨン Radiohalogenated agents for in situ immunomodulatory cancer vaccination
JP7438756B2 (en) * 2016-07-25 2024-02-27 ウイスコンシン アラムナイ リサーチ ファウンデーシヨン Targeted radiotherapeutic chelates for in situ immunomodulatory cancer vaccination
KR20200088374A (en) * 2017-11-10 2020-07-22 위스콘신 얼럼나이 리서어치 화운데이션 Methods of using targeted radiotherapy (TRT) to induce an anti-tumor immune response to immunotherapy
SG11202009550PA (en) * 2018-04-10 2020-10-29 Cellectar Biosciences Inc Fractionated dosing of a phospholipid ether analog for the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024480A1 (en) * 1996-12-04 1998-06-11 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US5795561A (en) * 1987-10-23 1998-08-18 The Board Of Regents Of The University Of Michigan Radioiodinated phospholipid ether analogues
WO2005084716A2 (en) * 2004-03-02 2005-09-15 Cellectar, Llc Phospholipid analogs for diagnosis and treatment of cancer
WO2006014589A2 (en) * 2004-07-08 2006-02-09 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795561A (en) * 1987-10-23 1998-08-18 The Board Of Regents Of The University Of Michigan Radioiodinated phospholipid ether analogues
WO1998024480A1 (en) * 1996-12-04 1998-06-11 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
WO2005084716A2 (en) * 2004-03-02 2005-09-15 Cellectar, Llc Phospholipid analogs for diagnosis and treatment of cancer
WO2006014589A2 (en) * 2004-07-08 2006-02-09 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEICHERT J P ET AL: "Initial Clinical Imaging Results with NM404 in Non-Small Cell Lung Cancer", MOLECULAR IMAGING, MIT PRESS,, US, vol. 3, no. 3, July 2004 (2004-07-01), pages 269 - 270, XP002365141, ISSN: 1535-3508 *

Also Published As

Publication number Publication date
WO2007013894A2 (en) 2007-02-01
JP2008545614A (en) 2008-12-18
EP1833514A2 (en) 2007-09-19
WO2007013894A9 (en) 2007-03-29
MX2007007497A (en) 2008-01-11
CA2591907A1 (en) 2007-02-01
KR20080005178A (en) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2007013894A3 (en) Phospholipid ether analogs for detecting and treating cancer
MX2009012906A (en) Monoclonal antibodies against claudin-18 for treatment of cancer.
Hu et al. miR-124 inhibits growth and invasion of gastric cancer by targeting ROCK1
Zebary et al. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma
WO2005084716A3 (en) Phospholipid analogs for diagnosis and treatment of cancer
MX346973B (en) Tumor specific antibodies and uses therefor.
PH12018502572A1 (en) 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer
WO2006052823A3 (en) Biomarkers for prostate cancer metastasis
WO2011079133A3 (en) Compounds and methods for kinase modulation, and indications therefor
MY141605A (en) Method of treating certain cancers using an estrogen agonist/antagonist
WO2004045521A3 (en) Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr
WO2009038754A3 (en) Gene expression signatures in enriched tumor cell samples
WO2006012646A3 (en) Amacr cancer markers
WO2009049214A3 (en) Inhibition and treatment of prostate cancer metastasis
DK1802625T3 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors of CDK2 and angiogenesis and in the treatment of breast, colon, lung and prostate cancer
IL266563B (en) Heterocyclic compounds useful as pdk1 inhibitors
MY183404A (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
NZ596365A (en) Pentamidine combinations for treating cancer
HK1131165A1 (en) Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
TR201802090T4 (en) Monoclonal anti-GT468 antibodies for the treatment of cancer.
MX2009013765A (en) Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof.
EP2504363A4 (en) Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
MX2022013783A (en) Copper-containing theragnostic compounds and methods of use.
WO2008104805A3 (en) Proteins
EP1654377A4 (en) Shc PROTEIN-RELATED METHODS AND COMPOSITIONS FOR THE PROGNOSIS OF BREAST, PROSTATE AND OVARIAN CANCER

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11382645

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11382645

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2591907

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/007497

Country of ref document: MX

Ref document number: 2007548624

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005858499

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077016834

Country of ref document: KR